Updates are available Correction dated 2020-04-01
Click to view Correction: https://doi.org/10.1136/jitc-020-0755-1corr1
-
Authors
Zhu, Li
Narloch, Jessica L.
Onkar, Sayali
Joy, Marion
Broadwater, Gloria
Luedke, Catherine
Hall, Allison
Kim, Rim
Pogue-Geile, Katherine
Sammons, Sarah
Nayyar, Naema
Chukwueke, Ugonma
Brastianos, Priscilla K.
Anders, Carey K.
Soloff, Adam C.
Vignali, Dario A. A.
Tseng, George C.
Emens, Leisha A.
Lucas, Peter C.
Blackwell, Kimberly L.
Oesterreich, Steffi
Lee, Adrian V. http://orcid.org/0000-0001-9917-514X
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30CA047904)
Fashion Footwear Association of New York
Nicole Meloche Memorial Breast Cancer Research Foundations
Penguins Alumni Foundation
Shear Family Foundation
TL-1 CTSA Pre-Doctoral Training Grant (5TL1TR001116-03)
Duke Cancer Institute Core Grant (P30CA014236)
Magee-Womens Research Institute and Foundation
Susan G. Komen for the Cure, Komen Wyoming Affiliate
Innovative Cancer Research
- License Information
-
More Information
Article History
Received: 23 June 2019
Accepted: 20 September 2019
First Online: 18 October 2019
Ethics approval and consent to participate
: Ethics approval and consent to participate were approved under the University of Pittsburgh IRB # PRO11100645, 14040193, 1500502, 1602030.
: Not applicable.
: PKB receives Speaker’s Honoraria from Genentech-Roche and Merck; research funding from Pfizer and Merck; and is a consultant in Eli Lilly, Merck, and Angiochem. CA receives research funding and serves an uncompensated advisory role for Novartis, Merrimack, Lily, Seattle Genetics, Nektar, Tesaro. CA receives research funding from Merck, Tesaro, PUMA, and G1-Therapeutics. CA has a compensated consultant role with Merck, PUMA and Eisai, and uncompensated advisory role with Genentech. CA receives royalties from UpToDate, Jones and Bartlett. ACS receives Susan G. Komen Foundation Career Catalyst Research award (CCR15329745). DAAV owns stock in TTMS, Tizona, Oncorus, BMS; patents licensed in Tizona, BMS, Astellas; grants from BMS; Scientific Advisory Board in Tizona, Oncorus, F-Star, Pieris; and consultancy in Crescendo, Intellia, MPM, Onkaido, Servier. LE reports grants and non-financial support from Roche/Genentech, Corvu; grants and personal fees from AstraZeneca; grants from EMD Serono; personal fees from Syndax, Amgen, Medimmune, AbbVie, Gristone Oncology, Peregrine, Celgene, eTHeRNA; non-financial support from Bristol-Myers Squibb; grants, personal fees and non-financial support from Aduro Biotech, Bayer, Replimune, Novartis, Macrogenics, Vaccinex, Maxcyte; personal fees and other from Molecuvax; grants from Merck; and member, FDA Advisory Committee on Cell Tissue and Gene Therapies; member, Board of Directors for Society of Immunotherapy of Cancer. PCL owns stock in Amgen (AMGN) and his spouse KP-G has consulted for Bayer/Loxo. KLB is an employee of Eli Lilly. SO is a member of the Scientific Advisory Panel for NSABP.
